Author | Melgaço, Juliana Gil | |
Author | Gardinali, Noemi Rovaris | |
Author | Mello, Vinicius da Motta de | |
Author | Leal, Mariana | |
Author | Lewis-Ximenez, Lia Laura | |
Author | Pinto, Marcelo Alves | |
Access date | 2018-06-05T13:28:26Z | |
Available date | 2018-06-05T13:28:26Z | |
Document date | 2018 | |
Citation | MELGAÇO, Juliana Gil; et al. Hepatitis E: Update on Prevention and Control. BioMed Research International, Volume 2018, Article ID 5769201, 9p, 2018. | pt_BR |
ISSN | 2314-6133 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/26720 | |
Language | eng | pt_BR |
Publisher | Hindawi Publishing Corporation | pt_BR |
Rights | open access | pt_BR |
Subject in Portuguese | Hepatite E | pt_BR |
Subject in Portuguese | Vírus da Hepatite E | pt_BR |
Subject in Portuguese | Transmissão | pt_BR |
Subject in Portuguese | Diagnóstico | pt_BR |
Subject in Portuguese | Tratamento | pt_BR |
Subject in Portuguese | Vacinação | pt_BR |
Subject in Portuguese | Epidemiologia | pt_BR |
Title | Hepatitis E: Update on Prevention and Control | pt_BR |
Type | Article | pt_BR |
DOI | 10.1155/2018/5769201 | |
Abstract | Hepatitis E virus (HEV) is a common etiology of acute viral hepatitis worldwide. Recombinant HEV vaccines have been developed, but only one is commercially available and licensed in China since 2011. Epidemiological studies have identified genotype 3 as the major cause of chronic infection in immunocompromised individuals. Ribavirin has been shown to be effective as a monotherapy to induce HEV clearance in chronic patients who have undergone solid organ transplant (SOT) under immunosuppressive therapy. Efforts and improvements in prevention and control have been made to reduce the instances of acute and chronic hepatitis E in endemic and nonendemic countries. However, this review shows that further studies are required to demonstrate the importance of preventive vaccination and treatment worldwide, with emphasis on hepatitis E infection in the public health system. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Ambulatório. Rio de Janeiro, RJ. Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz.Laboratório de Desenvolvimento Tecnológico em Virologia. Rio de Janeiro, RJ. Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Ambulatório. Rio de Janeiro, RJ. Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Ambulatório. Rio de Janeiro, RJ. Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Ambulatório. Rio de Janeiro, RJ. Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Ambulatório. Rio de Janeiro, RJ. Brasil. | pt_BR |
Subject | Hepatitis E | pt_BR |
Subject | Hepatitis E Virus, | pt_BR |
Subject | Transmission | pt_BR |
Subject | Diagnosis | pt_BR |
Subject | Epidemiology | pt_BR |
Subject | Vaccination | pt_BR |
Subject | Treatment | pt_BR |
e-ISSN | 2314-6141 | |